Xenon Pharmaceuticals (XENE) EBIT (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of EBIT data on file, last reported at -$112.3 million in Q1 2026.

• EBIT for Q1 2026 came in at -$112.3 million, down 54.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$412.7 million (down 40.84% YoY), and the FY2025 annual result was -$373.1 million, down 33.57% from the prior year.
• EBIT retreated to -$112.3 million in Q1 2026 per XENE's latest filing, from -$109.8 million in the prior quarter.
• Over five years, EBIT peaked at -$17.4 million in Q1 2022 and troughed at -$112.3 million in Q1 2026.
• A 5-year average of -$65.2 million and a median of -$59.0 million in 2024 frame the typical range for EBIT.
• On a YoY basis, EBIT climbed as much as 8.16% in 2022 and fell as far as 231.89% in 2022.
• A 5-year view of EBIT shows it stood at -$43.3 million in 2022, then retreated by 23.92% to -$53.7 million in 2023, then slumped by 44.29% to -$77.5 million in 2024, then slumped by 41.68% to -$109.8 million in 2025, then dropped by 2.33% to -$112.3 million in 2026.
• Business Quant data shows XENE's EBIT at -$112.3 million in Q1 2026, -$109.8 million in Q4 2025, and -$96.3 million in Q3 2025.